Recent Publications by CFE Educators

Recent Published articles, books, and other scholarship by Academy members, CFE Education Scientists, and CFE Faculty.
Design and Implementation of an Innovative, Longitudinal Wellness Curriculum in an Anesthesiology Residency Program.
2021
Authors: Thornton KC, Sinskey JL, Boscardin CK, Sullivan KR
Sexual Debut Among Heterosexual Men of African and Caribbean Descent: Are the Youth Initiating Sex Earlier than the Older Generation?
2021
Authors: Konkor I, Mkandawire P, Antabe R, Luginaah I, Husbands W, Wong J, Lawson E, Etowa J, Omorodion F, McIntosh MD
Herpes simplex virus-2 associated with a large fungating penile mass.
2021
Authors: Bowman MS, Lang UE, Leslie KS, Amend G, Breyer BN
A 48-year-old male with HIV/AIDS presented with an enlarging nodular lesion on the base of his penis. Histology revealed changes consistent with chronic viral infection and culture grew herpes simplex virus 2 (HSV-2). The lesion was refractory to valacyclovir and intralesional (IL) cidofovir therapy. Urology excised the mass and the defect was repaired primarily with good cosmetic result. Post-operative pathology confirmed HSV-2 despite the unusual appearance of the lesion consisting of nodular mass without gross ulceration.
View on PubMedPrimary nasal Kaposi Sarcoma in well-controlled HIV-positive patient with normal CD4 count associated with long-term nasal steroid use.
2021
Authors: Htet KZ, Waul M, Edelstein H, Mui S, Cherny S, Leslie K
Kaposi sarcoma (KS) is an angioproliferative disease that is caused by human herpesvirus 8. The epidemic form of KS is associated with acquired immunodeficiency syndrome (AIDS) and is common in HIV-positive patients with CD4 counts less than 200 cells/mm. We present the case of a 63-year-old man with well-controlled HIV and normal CD4 count developing atypical nasal KS associated with intranasal steroid use.
View on PubMedDifficulty Taking Medications: a Corollary to Dementia Risk.
2021
Authors: Chen P, Covinsky K
CoachMS, an innovative closed-loop, interdisciplinary platform to monitor and proactively treat MS symptoms: A pilot study.
2021
Authors:
Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care Samples.
2021
Authors: Lee W, Straube S, Sincic R, Noble JA, Montoy JC, Kornblith AE, Prakash A, Wang R, Bainton RJ, Kurien PA
Analysis of Active and Passive Tobacco Exposures and Blood Pressure in US Children and Adolescents.
2021
Authors: Levy RV, Brathwaite KE, Sarathy H, Reidy K, Kaskel FJ, Melamed ML
IMPORTANCE
Hypertension is a leading cause of cardiovascular disease in adults; preclinical associations between hypertension and cardiovascular disease are seen in childhood. Nicotine is a known toxin, but its association with pediatric hypertension is unclear.
OBJECTIVE
To test the hypothesis that tobacco exposure is associated with the presence of elevated blood pressure in US children and adolescents and that this association is dose dependent.
DESIGN, SETTING, AND PARTICIPANTS
This cross-sectional study used data from the 2007 to 2016 National Health and Nutrition Examination Survey (NHANES), a population-based nationally representative sample of US children and adolescents. Children were eligible if they were aged 8 to 19 years at the time of participation in the main NHANES study. Exclusion criteria included those of the main NHANES study, inability to complete testing, or missing questionnaires. Of the 10 143 participants in NHANES aged 8 to 19 during the study years, 8520 were included in the analysis. Analysis was conducted from October 12, 2019, to July 9, 2020.
EXPOSURES
Tobacco exposure, defined as serum cotinine levels greater than 0.05 µg/L, or reporting living with a smoker or smoking themselves.
MAIN OUTCOMES AND MEASURES
Elevated blood pressure, classified as greater than 90% for a child's age, sex, and height according to the 2017 American Academy of Pediatrics Clinical Practice Guidelines. The a priori hypothesis that there is a positive association between tobacco exposure and elevated blood pressure in the study population was tested. Analysis included logistic regression with adjustment for possible confounders. Subgroup and sensitivity analyses were conducted.
RESULTS
A total of 8520 children were included in the analysis, representing 41 million US children. The mean (SD) age of the participants was 13.1 (0.05) years, 51% (95% CI, 49%-52%) were male, and 58% (95% CI, 54%-62%) were non-Hispanic White individuals. Participants with any tobacco smoke exposure were more likely than those without exposure to be older (mean [SD] age, 13.3 [0.07] years vs 12.8 [0.06] years), male (53% [95% CI, 51%-55%] vs 49% [95% CI, 47%-50%]), and non-Hispanic Black individuals (19% [95% CI, 16%-22%] vs 10% [95% CI, 8%-12%]). The odds of having elevated blood pressure was 1.31 (95% CI, 1.06-1.61) for any tobacco exposure after adjustment; odds were similar across subgroups and remained significant in multiple sensitivity analyses.
CONCLUSIONS AND RELEVANCE
This study suggests that tobacco exposure is associated with elevated blood pressure in US children and adolescents. This modifiable risk factor represents a target for further research into reducing hypertension in children and adolescents.
View on PubMedShort-term chemosensory distortions and phantoms in COVID-19.
2021
Authors: Gurrola JG, Chang JL, Roland LT, Loftus PA, Cheung SW
OBJECTIVE
To identify differentiation features of chemosensory dysfunction in COVID-19 infection and their primary drivers.
STUDY DESIGN
Cross-sectional cohort comparison.
METHODS
A national anonymous survey was used to query participants regarding nasal symptoms and chemosensory dysfunction including sensitivity levels, and presence or absence of distortions and phantoms within the 6-week time window surrounding their COVID-19 testing and survey completion.
RESULTS
Three-hundred and sixty-four respondents who reported COVID-19 positive (COVID+; n = 176) or COVID-19 negative (COVID-; n = 188) test results completed the survey. The COVID+ cohort had higher occurrence rates for: (a) chemosensory sensitivity impairments (67.0% vs 30.3%; .01), where the rate of complete loss of smell (anosmia) or taste (ageusia) was higher (35.8% vs 4.8%; .01), and (b) chemosensory distortions (39.8% vs 19.1%; .01), where the rate of anosmia or ageusia with distortions was also higher in the COVID+ cohort (19.9% vs 2.7%; .01). Occurrence rates in the two cohorts were similar for chemosensory phantoms (COVID+ 17.0%, COVID- 18.6%; = .70) and nasal discharge or stuffiness in the presence of sensitivity impairment (COVID+ 63.6%, COVID- 52.6%; = .17).
CONCLUSION
Chemosensory dysfunction in COVID-19 is associated with higher rates of smell or taste sensitivity impairments and distortions. Higher rates of anosmia and ageusia drive these key findings. Chemosensory phantoms and nasal symptoms in the presence of sensitivity impairment occur at rates that should demand clinical attention, but they do not appear to be specific to COVID-19 positivity.
LEVEL OF EVIDENCE
2b.
View on PubMedRapid Adoption of Video Visits and Return-to-Clinic Procedures to Maintain Access to Allergy/Immunology Care Delivery During COVID-19.
2021
Authors: Lulu Tsao, Stephanie Anne Villanueva Ferraris, David Pines, Eugene Choo, Michele Pham, Monica Tang, Lorianna Leard, Andrew Gross, Cameron Ashbaugh, Lei Choi, Iris Otani